AbbVie's Acquisition of Apogee Therapeutics Could Strengthen Its Position as a Dividend King
AbbVie, already recognized as a 'Dividend King,' is acquiring Apogee Therapeutics for $10.9 billion to bolster its drug portfolio and maintain growth after the loss of patent protection on Humira in 2023. The deal includes late-stage candidates like zumilokibart for atopic dermatitis, which aligns with AbbVie's therapeutic focus.
